IngredientsIn the context of dietary supplements and functional nutrition, the term marine colloids refers to a group of high-molecular-weight polysaccharides extracted from marine macroalgae (seaweeds). They are more precisely designated phycocolloids or seaweed hydrocolloids. The word "colloid" reflects their ability to form stable colloidal dispersions or gels in aqueous media, a fundamental physicochemical property that underpins both their industrial utility and their biological activity in the gastrointestinal tract.
Marine macroalgae (seaweed) are a rich source of bioactive polysaccharides such as agar, carrageenan, and alginate. These three compounds are classified as food additive ingredients, widely used as gelling, thickening, stabilizing, and emulsifying agents in the food, nutraceutical, pharmaceutical, and cosmetic industries.
The polysaccharides in this group include carrageenan, agar, agarose, and porphyran from red seaweed; fucoidan, laminarin, and alginate (alginic acid) from brown seaweed; and ulvan from green seaweed. In commercial and supplement contexts, the three dominant phycocolloids are carrageenan, agar, and alginate, along with the bioactive brown-algae polysaccharides fucoidan and laminarin.
Classified by pigmentation, there are three taxonomic groups, including red algae (Rhodophyta), brown algae (Ochrophyta, Phaeophyceae), and green algae (Chlorophyta). Each taxonomic group produces characteristic polysaccharides with distinct chemical architectures.
Carrageenan is a high-molecular-weight, strongly anionic polymer derived from several species of red seaweed that is used for the textural stabilization of foods. Carrageenans are polysaccharides composed of D-galactose and 3,6-anhydro-D-galactose sulfate. Their chemical structure is heterogeneous and classified based on the number and position of sulfate esters and the location of the 3,6-anhydro-bridge in (1→4)-linked galactopyranose molecules.
There are three major types of carrageenan found in red algae: kappa (κ)-, iota (ι)-, and lambda (λ)-carrageenan. Kappa (κ)- contains only one sulfate group, iota (ι)- contains two sulfate groups, and lambda (λ)- contains three sulfate groups. These structural differences confer different physical behaviors: kappa carrageenan forms gels in the presence of potassium ions, iota carrageenan forms gels in the presence of calcium ions, while lambda carrageenan does not form gels in the presence of potassium or calcium ions.
Principal commercial sources include: Kappaphycus alvarezii, the most common kappa-carrageenan source, primarily farmed in Asian countries such as Indonesia, the Philippines, Vietnam, and Malaysia. Kappa is also obtained from Chondrus crispus; iota carrageenan is obtained from Eucheuma spinosum. Carrageenan is primarily produced through aquaculture-based seaweed farming, with Eucheuma and Kappaphycus species accounting for more than 90% of global output.
Agar or agar-agar is a gelatinous substance obtained from an alga which consists of a mixture of agarose and agaropectin. This was discovered in 1658 by Minora Tanzaemon in Japan, where it is called kanten. It can be used as a laxative, an appetite suppressant, as a vegetarian gelatin substitute, a thickener in soups, in fruit preserves, ice cream, and other desserts, as a clarifying agent in brewing, and for sizing paper and fabrics.
Agar and carrageenan are extracted from certain types of red algae. Agarose, the principal gelling component of agar, is a neutral polysaccharide built from alternating 3-linked β-D-galactopyranose and 4-linked 3,6-anhydro-α-L-galactopyranose units, while agaropectin is the sulfated, partially methylated fraction that makes up the remainder of the mixture.
Alginate is the main polysaccharide of brown seaweed, mainly from kelps (large brown seaweeds). Alginate is an anionic polymer based on β-D-mannuronic acid and 1,4-α-L-guluronic acid monomers. It is commercially produced primarily from genera such as Laminaria, Macrocystis, Ascophyllum, and Ecklonia. Alginates are salts of alginic acid. The alginates of alkali metals — in particular sodium alginate, potassium alginate, and magnesium alginate — are soluble in water, while calcium alginate is not water-soluble.
Fucoidans, discovered in 1913, are fucose-rich sulfated polysaccharides extracted mainly from brown seaweed. Fucoidan is a long-chain, sulfated, fucose-rich polysaccharide found in the cell walls of Phaeophyceae (brown algae). Key commercial source species include Fucus vesiculosus, Laminaria japonica, Undaria pinnatifida, and Ascophyllum nodosum.
Structurally, laminarin is composed of β-(1,3)-linked glucose containing large amounts of sugars and a low fraction of uronic acids. The most dominant polysaccharides in brown seaweeds are laminarin and alginic acid.
These hydrocolloids are considered as food additives, and are generally recognized as safe by the US Food and Drug Administration and the European Food Safety Authority, and they have the following E numbers in the European Union: refined carrageenan has E number E 407 (includes furcelleran), semi-refined carrageenan has E 407a, agar has E 406, and alginates have several E numbers as follows: E 400 (alginic acid), E 401 (sodium alginate), E 403 (ammonium alginate), E 404 (calcium alginate) and E 405 (propane-1,2-diol alginate).
Marine colloids are available in a variety of commercial forms depending on their intended use:
Unlike synthetic compounds with specified structures, seaweed polysaccharides exhibit substantial structural heterogeneity due to variations in species, habitat, and processing, affecting bioactivity, digestibility, and interactions within the gastrointestinal tract.
Archaeological evidence from several sources suggests that seaweeds have been used in traditional medicine for millennia in China (2700 BCE), Egypt (1550 BCE), Japan (13,000–300 BCE), and India (300 BCE).
Seaweeds have been used since ancient times as food, mainly by Asian countries, while in Western countries, their main application has been as gelling agents and colloids for the food, pharmaceuticals, and the cosmetic industry.
Throughout numerous parts of the globe, particularly in East Asian nations like China, Korea, and Japan, a wide range of seaweed species have been an integral part of both traditional medicine and the food industry, with a history spanning more than six centuries. Traditional Chinese medicine used hot water extracts of several types of seaweed in the treatment of cancer. Additionally, the Japanese and Chinese cultures used seaweed to treat goiter and other glandular problems as long ago as 300 BC. The iodine content of seaweed is now understood to explain this traditional use for thyroid-related conditions.
Many species of seaweeds have been used in traditional medicine, especially in Asian countries, against goiter, nephritic diseases, and anthelmintics.
Agar as a distinct preparation has a particularly well-documented Japanese origin: agar was discovered in 1658 by Minora Tanzaemon in Japan, where it is called kanten. For centuries afterward, it was prepared by freezing and thawing seaweed extracts to produce a dried gel used in traditional Japanese cuisine and as a digestive aid.
Although in Asia, red seaweeds (such as carrageenans) have been consumed for centuries as food products or food supplements for health promotion, this group of polysaccharides were originally described in an Irish coastal known as Carragheen, from which the name is derived. Carrageenan from Chondrus crispus (Irish moss) has been used in Ireland and the broader Atlantic region for centuries as a cough remedy and food thickener, with extracts prepared by boiling the dried weed in milk.
The usage of brown algae has a long history for almost 3000 years among the Tongan people. They called it Limu Moui and believed that it would give them longevity and overall good health; in 1777 when Captain Cook visited Tonga, the Tongans offered him Limu Moui to restore his strength and energy.
Seaweed in the Mediterranean region was used for medicinal and animal feed purposes and as a dye during the ancient Greek and Roman eras. Red algae found in the Mediterranean was used to treat parasitic worms, a practice dating back to the pre-Christian era. The Romans used seaweed in the treatment of wounds, burns, and rashes. In Scotland during the 18th century, physicians used dried seaweed stem to successfully drain abdominal wall abscesses.
Carrageenans were introduced in industry in the early 1930s. They were first used in China around 600 BCE. In Ireland, Chondrus crispus was traditionally boiled with milk, producing a thick gel consumed as a remedy for respiratory ailments and as a general tonic. The Philippines subsequently became the world's leading supplier; the Philippines is the current largest producer of carrageenan where the supply is about 80% of cultivated seaweed to the world industry.
The diverse and complex structures of seaweed polysaccharides, shaped by sulfation patterns, glycosidic linkages, and monosaccharide composition, contribute to their broad-spectrum biological activities, including antimicrobial, immunomodulatory, and prebiotic functions.
The bio-properties of polysaccharides are strictly dependent on their chemical characteristics and structure, which varies depending on the species, their life cycles, and other biotic and abiotic factors.
The "egg-box" model is the central mechanistic framework for alginate gelling behavior: alginate, a naturally occurring polysaccharide derived from brown algae, has emerged as a versatile cornerstone in the field of biomedical materials. Its widespread adoption is driven by its exceptional biocompatibility and the unique cation-dependent gelation defined by the "egg-box" model. In this model, divalent cations (particularly calcium) cross-link the guluronate blocks of adjacent alginate chains, creating a structured hydrogel matrix that is responsible for alginate's viscous and film-forming properties.
All three principal marine colloids — agar, carrageenan, and alginate — function as non-digestible dietary fibers in the human gastrointestinal tract. Sodium alginate is not readily digested or absorbed by the human body. It is considered a soluble dietary fiber that passes through the gastrointestinal tract largely intact. The human digestive system lacks the enzymes necessary to break down the glycosidic bonds within sodium alginate.
Alginate's viscous gel formation in the stomach is proposed as a key mechanism for its effects on satiety and nutrient absorption. The effects of sodium alginate on cholesterol excretion and glucose tolerance may be due to the inhibition of cholesterol and glucose absorption from the small intestine by the gelling of free alginic acid converted in the stomach.
Agar-agar is approximately 80% dietary fiber, so it can serve as an intestinal regulator. Its bulking quality has been behind fad diets in Asia, for example the kanten (the Japanese word for agar-agar) diet. Once ingested, kanten triples in size and absorbs water, resulting in the consumer feeling fuller.
Fucoidan and laminarin modulate host immune responses by activating immune cells (macrophages, neutrophils, T lymphocytes) and inducing the expression of cytokines (TNFα, IL-1β, IL-6, IL-8, NF-κB).
Fucoidans are versatile and nontoxic marine-origin heteropolysaccharides with a wide range of favorable biological activities, including antitumor, immunomodulatory, antiviral, antithrombotic, anticoagulant, antioxidant, and lipid-lowering activities. In the early 1980s, fucoidans were first recognized for their role in supporting the immune response and later, in the 1990s, their effects on immune potentiation began to emerge.
The sulfated nature of carrageenan and fucoidan is central to their antiviral properties. Sulfated polysaccharides can compete with heparan sulfate proteoglycans on cell surfaces, blocking viral attachment to host cells. Fucoidan extracted from brown seaweed possesses various biological functions including anti-inflammatory, immunomodulatory, antitumour, antibacterial, antiviral, anticoagulant, antioxidant, neuroprotective, cardio-protection and growth-promoting effects.
Marine-algal polysaccharides (fucoidan, alginate, laminarin, carrageenan, and ulvan) act as fermentable fibers that enhance short-chain fatty acid (SCFA) production and enrich beneficial gut microbial populations. Alginate, a polysaccharide from algae, has been reported to have various benefits including positive effects on gastrointestinal and cardiovascular health, and may act as a dietary fiber.
The sulfate groups in fucoidan and carrageenan confer heparin-like anticoagulant properties. These molecules can inhibit thrombin directly and potentiate antithrombin activity, though the clinical significance of orally ingested doses has not been established as equivalent to injectable heparin.
Clinical evidence (alginate): A pilot study in overweight male subjects demonstrated that treatment with a 1.5 g dose of a strong-gelling alginate may reduce cholesterol and glucose uptake. Treatment with a 1.5-g dose of a strong-gelling alginate may restore uptake of cholesterol and glucose to the levels of healthy subjects. These data indicate a potential therapeutic application of gelling fibers.
Only a study focused on obese adults with an energy-restricted diet (Georg Jensen et al., 2012) and a clinical trial of six obese adults (Reichert et al., 2013) demonstrated that alginate reduced weight in subjects. The alginate's weight loss effect on normal-weight or overweight adults is unclear, and the mechanism also needs further research.
Prebiotic classification: In Japan, marine colloids have been formally recognized as functional fibers. Prebiotic fiber functional ingredients include the very popular indigestible dextrin, as well as psyllium seed husk, polydextrose, partially hydrolyzed guar gum, wheat bran, rafinose, beer yeast fiber, low molecular weight sodium alginate, and agar-derived fiber — all of which appear in the Japan Foods for Specified Health Uses (FOSHU) approved category.
Laxative effects (agar): Taking a product containing agar gel (Slim Kanten) by mouth daily while following a traditional Japanese diet for 12 weeks appears to reduce body weight and body mass index in obese people with type 2 diabetes and impaired glucose tolerance more effectively than following a traditional Japanese diet alone. Evidence strength here is limited: this is a single small trial, and independent replication is limited.
Evidence strength: Prebiotic and fiber-related mechanisms are plausible and supported by in vitro and animal data; human clinical data are sparse, often limited to small pilot studies, and methodologically heterogeneous.
Systematic review evidence: A meta-analysis of randomized clinical trials reported that macro-algae supplementation significantly decreased serum levels of total cholesterol (WMD = −6.7 mg/dL; 95% CI: −12.59, −0.80; p = 0.026) and LDL cholesterol (WMD = −8.25 mg/dL; 95% CI: −15.38, −1.12; p = 0.023). There was an increase in HDL cholesterol (WMD = 0.48 mg/dL; 95% CI: −2.05, 3.01; p = 0.71) which was not statistically significant.
Sodium alginate RCT: A randomized double-blind controlled trial was conducted on hypercholesterolemic patients (TC ≥ 5.2 mmol/L, n = 84) to investigate the effects of sodium alginate (SA) on serum total cholesterol levels. SA showed no significant effects on body weight or body mass index (BMI). However, SA reduced lipid levels: the changes in TC, TG, and LDL-C in the SA intervention group were higher compared to the control group (p < 0.05).
Mechanism (animal data): Sodium alginate preparations enhanced cholesterol excretion into feces, and inhibited blood glucose and insulin levels from rising 30 minutes after glucose administration in rat models. The increased conjugated bile acids in feces and indifferent serum bile acids indicate that alginate (as a dietary fiber) enhanced bile acid excretion. Similarly, low-molecular-weight sodium alginate increased cholesterol excretion in feces in rats. However, the current studies on associations between alginate and bile acids were mostly limited to animal experiments.
Evidence strength: Modest lipid-lowering effects are supported by a small number of human RCTs and one meta-analysis, but heterogeneity in algae types, doses, and study populations limits conclusions. Further powered trials are needed.
Dietary fiber consumption is associated with weight loss, and a number of clinical trials of alternative treatments with dietary fibers have been conducted. Sodium alginate, due to its anti-inflammatory and postprandial blood glucose-reducing properties, is marketed as a weight loss supplement either as a standalone product or as a food additive.
The PGX complex (containing sodium alginate with konjac glucomannan and xanthan gum) has been studied in clinical settings: isolated soluble fiber supplementation improves anthropometric and metabolic outcomes in overweight and obese adults, thereby indicating that supplementation may improve fiber intake and health in these individuals. However, the interpretation of these findings warrants caution because of the considerable between-study heterogeneity.
Evidence strength: Preliminary. The satiety and glycemia evidence is mechanistically plausible and supported by small clinical trials and animal studies, but large, independently replicated human RCTs with standardized alginate preparations are lacking.
In recent years, the understanding of the immunomodulatory effects of fucoidan has expanded significantly. The ability of fucoidan(s) to activate CTL-mediated cytotoxicity against cancer cells, strong antitumor property, and robust safety profile make fucoidans desirable for effective cancer immunotherapy.
A human supplementation study is referenced in the literature regarding fucoidan and influenza vaccination: supplementation of elderly Japanese men and women with fucoidan from seaweed increased immune responses to seasonal influenza vaccination. This represents one of the few direct human clinical data points for fucoidan's immunomodulatory effects, though as a single study it requires independent replication.
Evidence strength: Animal and in vitro immunomodulatory evidence is robust. Human clinical data is preliminary, with few small trials. Fucoidan's immunopotentiating activity is an active area of research.
Fucoidan has potent antiviral activity on SARS-CoV-2 (COVID-19) viral infection in preclinical studies. Laminarin also has potential antiviral activity on HIV, is reported to possess prebiotic activity on microbial gut health, and has antitumor activity.
The bioactivity and physicochemical characteristics of fucoidan have been demonstrated to include antitumour, immunomodulatory, and antiviral effects. Fucoidan may also assist in the development of effective treatments for tissue engineering and other skincare applications.
Evidence strength: Almost entirely preclinical (in vitro and animal). No adequately powered human clinical trials of marine colloids specifically as antiviral interventions have been completed and published. This area is considered preliminary.
Previous studies report that laminarin enhances wound repair and stimulates tissue regeneration, collagen deposition, and re-epithelialisation. In previous studies, seaweed polysaccharides with different molecular weights were compared with crude samples and shown to be potent inducers of wound closure and beneficial in treating burns by improving cell migration and proliferation during wound repair.
Calcium alginate is used clinically as a wound dressing material due to its gel-forming capacity and biocompatibility; this is an established pharmaceutical (not supplement) application. Evidence for wound healing from orally ingested marine colloids specifically remains preclinical.
Evidence strength: In vitro and animal evidence exists for several marine colloids (notably laminarin and alginate) in wound healing contexts. Topical/medical device applications have established precedent, but oral supplementation for wound healing lacks controlled human data.
In vitro research has shown that laminarin and fucoidan from brown seaweeds showed anticancer activity by forming DNA smear on both colon (HT-29) and liver (HepG2) cancer cell lines, respectively, by inducing necrotic factors. Based on this investigation, laminarin and fucoidan are potential bioactive compounds for the treatment of cancer.
All laminarin and fucoidan samples investigated were demonstrated to have antioxidant, anti-inflammatory, and antidiabetic activity and could contribute to cancer cell death and inhibit cell proliferation.
Further research is necessary to demonstrate the biological potential of laminarin and fucoidan bioactives for glioblastoma, cancer, and other related diseases.
Evidence strength: All cancer-related evidence is at the in vitro or early preclinical stage. No human clinical trials have established therapeutic benefit of oral marine colloids against any cancer.
Sodium alginate has the strongest and most established clinical evidence base of any marine colloid, specifically for gastroesophageal reflux disease (GERD). Alginate is used in therapy as the sodium salt in disorders related to acid secretion, gastroesophageal reflux, heartburns and acid regurgitation. Upon contact with gastric acid, sodium alginate rapidly precipitates to form a viscous gel "raft" that floats on the stomach contents, providing a physical barrier against reflux. The discussion bridges the gap between polymer structure and diverse biomedical applications, including drug delivery, tissue engineering, and the clinical management of gastrointestinal reflux and wound care.
Evidence strength: This is the best-established human clinical application of a marine colloid. Alginate-based antireflux preparations (e.g., Gaviscon®) are licensed pharmaceutical products in multiple jurisdictions and have been demonstrated in multiple randomized trials to reduce GERD symptoms.
Agar has been studied specifically in the neonatal context. A meta-analysis reported decreased neonatal serum bilirubin with plain agar. This use is based on agar's capacity to bind bilirubin in the intestinal lumen and interrupt enterohepatic circulation, reducing serum bilirubin levels in jaundiced newborns. This is a specific and evidence-supported clinical use distinct from general supplementation.
The following dosages appear in the source literature and are reported here as stated in those sources. They do not constitute recommendations.
These hydrocolloids are generally recognized as safe by the US Food and Drug Administration and the European Food Safety Authority. The safety of carrageenans in foods has been debated, but based on their safe use history and acute and chronic toxicology tests, carrageenans are recognized as safe both by the US Food and Drug Administration and the European Food Safety Authority.
For alginates specifically: EFSA conducted the safety re-evaluation for alginic acid and its salts of sodium, potassium, ammonium, and calcium as food additives and derived the following conclusions: no safety concern and no need to establish an ADI as an additive used in food. The usage for infants and young children should be below therapeutic dosages. JECFA set alginate's ADI in 1992 as "not specified," meaning no specific limit is necessary due to its safety.
The EFSA panel considered that there was no indication for immunotoxicity or for an allergenic potential of alginic acid and its salts used as food additives. In human studies, the oral intake of sodium alginate was well tolerated.
Carrageenan is the subject of ongoing scientific debate about its gastrointestinal effects. While classified as generally recognized as safe (GRAS) for human consumption, numerous studies since the 1980s have suggested that carrageenans, particularly those with random coil conformations, may have adverse effects on gastrointestinal health, including aggravating intestinal inflammation. While these studies have provided some evidence of adverse effects, the topic is still controversial. Some have suggested that the negative consequence of the consumption of carrageenans may be structure dependent. Furthermore, pre-existing conditions may predispose individuals to varied outcomes of carrageenan intake.
An important distinction must be maintained between degraded carrageenan (poligeenan) and food-grade carrageenan: the substance poligeenan (formerly referred to as degraded carrageenan) is not a food additive. It exhibits toxicological properties at high doses that do not occur with the food additive carrageenan.
Confusion over nomenclature, basic carrageenan chemistry, type of carrageenan tested, interspecies biology, and misinterpretation of both in vivo and in vitro data has resulted in the dissemination of incorrect information regarding the human safety of carrageenan. The issue is exacerbated when mechanistic data obtained from in vitro experiments are directly translated to human hazard and used for risk assessment. This can lead to information that is taken out of experimental context and reported as a definitive effect in humans.
A small randomized pilot trial in patients with quiescent ulcerative colitis (n = 7) found that in this randomized trial the effects of food-grade carrageenan were neutral in this vulnerable patient group, suggesting short-term usage of food-grade carrageenan is safe. However, this study was too small to draw firm conclusions.
In long-term bioassays, carrageenan has not been found to be carcinogenic, and there is no credible evidence supporting a carcinogenic effect or a tumor-promoting effect on the colon in rodents. Also, like many dietary fibers, there is significant cecal enlargement in rodents when it is administered at high doses, but this does not appear to be associated with any toxicological consequences to the rodent. Many toxicological studies on carrageenan have involved administration at doses in excess of today's standards for dietary feeding levels in bioassays, and they are orders of magnitude in excess of those to which humans are exposed.
At high intake levels, all marine colloids capable of forming viscous gels can cause gastrointestinal symptoms. For the medicinal use of a combination of sodium alginate and magnesium alginate in infants and young children at maximum daily dosages ranging from 417 to 834 mg/kg body weight, constipation, diarrhoea, intestinal obstruction, flatulence, abdominal distension and bezoar are indicated as adverse effects. These adverse effects were observed at therapeutic (not food additive) doses in a vulnerable pediatric population.
Both agar and alginate are primarily nontoxic, and generally there is no dispute regarding their use as food ingredients.
Fucoidan extracted from brown seaweed possesses anticoagulant and antithrombotic activities. These heparin-like properties mean that fucoidan supplementation could theoretically potentiate the effects of anticoagulant drugs (e.g., warfarin, heparin, low-molecular-weight heparins) or antiplatelet agents. This is a pharmacologically plausible drug interaction, though specific human pharmacokinetic and pharmacodynamic interaction data remain limited.
As with dietary fibers generally, high intakes of viscous marine colloids may reduce the absorption of certain minerals through physical entrapment and increased intestinal transit. Alginate in particular has been studied in the context of mineral binding: 72.7 to 79.3% of administered alginates were excreted in feces within 3 days; alginates remained in the stomach for 2 hours, moving to the small intestine after 4 hours and eventually moving to the large intestine after 8 hours. Administration of the alginates did not affect Na, K, and Ca serum levels at the studied doses in animal research, suggesting no significant electrolyte perturbation at moderate intakes.
Although the safety of these compounds is generally accepted, there are still significant gaps in our understanding of their physicochemical behaviour. This highlights the need to develop a standardized digestion model to ensure their safety and evaluate their potential long-term health effects. The variability in molecular weight, degree of sulfation, and extraction methods across commercial preparations means that data from one product or species cannot necessarily be extrapolated to another, a key limitation for both safety assessment and efficacy claims.
Health conditions that Marine colloids may help support.
Body systems that Marine colloids may help support.
Go back